Mass testosterone screening of healthy male military personnel is not based on clinical evidence or guidelines and is unlikely to change battle readiness or health outcomes.

Medical Mythbusting Commentary for September , 2026

Source:
Pentagon issues clinical guidelines on troop testosterone screening to start immediately

Reference:
The CTV piece is a Reuters write-up of Defense Health Agency clinical guidance issued 2 September 2026. That guidance implements Secretary Hegseth’s 15 July 2026 memo requiring mandatory testosterone-deficiency screening for all active-duty and reserve members aged 30 and older during the annual Periodic Health Assessment, with optional testing under 30. Treatment, if offered, is voluntary. Women are not given routine T blood tests; they are screened for fatigue, menstrual disruption, and relative energy deficiency. The premise is that age-related or operationally suppressed testosterone impairs fatigue, performance, and “battle readiness,” and that force-wide screening plus targeted replacement will fix it.

That last claim is the part that does not hold up under current evidence.

What is actually true

Testosterone does decline after about age 30. Average total T falls roughly 1–2% per year. That is physiology, not a disease. Free T falls a bit more because SHBG rises. A single low number in a 32-year-old who just finished a field exercise, is sleep-deprived, or is in a caloric deficit is expected and often reversible with rest, food, and sleep.

Clinically confirmed hypogonadism can cause fatigue, reduced lean mass, low libido, and mood change. When a man has consistent symptoms plus two early-morning fasting total T values that are unequivocally low (commonly <264–300 ng/dL depending on the assay and guideline), replacement can improve sexual function, modestly increase lean mass and bone density, and sometimes improve energy. That is established for organic hypogonadism (testicular or pituitary disease). Benefits for “age-related” or functional low T in otherwise healthy middle-aged men are smaller and inconsistent.

Special operations personnel really can suppress T. “Operator Syndrome,” described by Frueh and colleagues in 2020, is a useful clinical construct: high allostatic load (repeated blast/TBI exposure, chronic sleep restriction, caloric deficit, high training volume) produces a cluster of TBI effects, sleep apnea, chronic pain, hormonal dysregulation including low T, and psychological sequelae. Some SOF cohorts show T levels that look like those of much older men. Deployment studies (e.g., Royal Marines in Afghanistan) show free T falling as SHBG rises with weight loss. That is real pathophysiology in a high-exposure subset, not the average 31-year-old reservist. Frueh himself has said operators sit at the extreme end of the spectrum and that blanket screening of the entire force is an open question.

Diagnosed hypogonadism in the broader force is uncommon. A large active-duty database found a coded hypogonadism prevalence of about 0.43%, rising with age and rank. TRT prescription rates in 2017 were ~4.7 per 1,000 men. Special Forces and EOD rates were higher, as expected. This is not a hidden epidemic across the Total Force.

What the guidelines and trials do not support

Major endocrine and urology societies recommend against population screening of asymptomatic men. The Endocrine Society’s 2018 guideline (and its 2026 statement after the Pentagon announcement) is explicit: diagnose only when symptoms and repeatedly low, accurately measured T are both present. Symptoms such as fatigue are nonspecific; obesity, opioids, sleep apnea, depression, overtraining, and poor sleep must be ruled out first. Age 30 is not a validated screening threshold.

The best military performance trials cut against the “give T and readiness rises” idea. In the Army-funded Optimizing Performance for Soldiers (OPS) studies, young eugonadal men given exogenous testosterone during severe energy deficit preserved lean mass but showed the same drop in strength and endurance as placebo. Raising T into or above the normal range did not protect military-relevant physical performance under operational stress. Treating a true deficiency is different from trying to “optimize” a normal or age-appropriate level.

Fatigue in a fighting force has many more common drivers than low T: sleep debt, TBI, PTSD, anemia, thyroid disease, relative energy deficiency, depression, and simple overtraining. A low T result does not establish that T is the cause, and replacing it will not fix those other problems.

Practical problems with mass screening at 30

Lab variability is large. Non-standardized assays can classify the same sample as “low” or “normal.” Guidelines require two morning fasting draws and, when total T is borderline, free T by a validated method.
False positives generate anxiety, extra visits, and pressure toward treatment in a culture that now frames T as “lethality.”
TRT suppresses spermatogenesis, raises hematocrit, can raise blood pressure (FDA label warning), and requires ongoing monitoring (PSA, Hct, fertility counseling). It is not a wellness supplement.
Applying an SOF-derived construct to the entire force over-medicalizes normal aging and operational stress that often remits with recovery.

The September guidance was briefly rescinded the same day for revision, which itself suggests the clinical pathway was not fully settled.

Bottom line for a clinician

The Secretary’s statement that T falls after 30 and that true deficiency can contribute to fatigue is factually correct. The leap from that fact to mandatory annual screening of every man over 30 in order to improve battle readiness is not supported by Endocrine Society or AUA guidelines, nor by the Army’s own performance trials. Operator Syndrome justifies targeted evaluation in high-exposure SOF and similar populations, not a force-wide lab mandate.

A more evidence-aligned approach is the one already used in civilian and most military practice: test men who have compatible symptoms (or high-risk exposures), confirm with proper morning assays, treat confirmed hypogonadism, and fix sleep, energy availability, and body composition first. Screening everyone at 30 will find many numbers that look “low” for a 25-year-old reference range and will not, on present data, make units more lethal.

Operator Syndrome is not a formal DSM or ICD diagnosis. It is a clinical construct introduced in 2020 by psychologist B. Christopher Frueh and colleagues after years of consultations with more than 50 U.S. special operations forces (SOF) operators and many of their partners. The paper appeared in the International Journal of Psychiatry in Medicine. Frueh later expanded it in the 2024 book Operator Syndrome.

The core idea is simple: a career in SOF produces an unusually high allostatic load—the cumulative wear of chronic threat, sleep restriction, caloric deficit, blast and impact exposure, and relentless training. The result is not “just PTSD.” It is a predictable cluster of medical, neurologic, endocrine, sleep, pain, cognitive, relational, and existential problems that travel together.

How it was identified

The original work was naturalistic, not a randomized cohort. Frueh’s group noticed the same pattern across Green Berets, SEALs, Marine Raiders, Air Force PJs, and similar units: operators in their mid-30s to 40s presenting with low mood, insomnia, irritability, fatigue, and poor concentration were being labeled PTSD or “adjustment issues,” while brain injury, hormones, and sleep apnea were rarely checked. When those systems were checked, the labs and studies often looked like those of much older men. That mismatch is the starting observation.

Later work has tried to operationalize it. A 2025 medRxiv analysis of SOF personnel used factor and latent-class methods across symptom domains and found that meeting five or more domains (especially headache, mental health, pain, sensory, and sleep) captured most of the variance. That is a research cut-point, not a settled diagnostic rule.

The constellation

Frueh’s original list is the one still cited:

Neurologic / sensory

Repeated mild TBI from blast (breaching, shoulder-fired weapons, IED proximity) and from impact (jumps, rucking, combatives, vehicle/helo vibration)
Headaches
Vestibular and visual problems
Memory, concentration, and processing-speed deficits

Endocrine

Hypogonadism / low testosterone (and sometimes broader HPA-axis and thyroid disruption)
Fatigue, low libido, impaired recovery that can look like depression

Sleep

Near-universal insomnia or fragmented sleep
Obstructive sleep apnea at rates that surprised clinicians—appearing in lean, fit men in their 30s–40s, often linked to TBI rather than obesity

Musculoskeletal

Chronic joint, back, and neck pain
Slow recovery from training load

Psychiatric / behavioral

Depression, anger, rumination, hypervigilance (“always on”)
Substance misuse
Suicide risk
Symptoms that may or may not meet full PTSD criteria

Relational / existential

Intimacy and marital strain
Difficulty transitioning out of the unit
Meaning and identity problems after a career defined by the team and the mission

These are not independent boxes. Poor sleep worsens pain and cognition. Low T and sleep apnea worsen mood and energy. Blast TBI can disturb both the HPA axis and sleep architecture. Treating one domain in isolation often fails.

Why testosterone shows up so often

Two mechanisms are repeatedly invoked:

TBI and hypothalamic–pituitary injury. Hypogonadism is a recognized sequela of brain injury. Blast exposure is thought to add a unique injury pattern (including interface astroglial scarring in some neuropathology series) beyond classic concussion.
Sustained operational stress and energy deficit. Sleep loss, underfeeding, and high training volume suppress the gonadal axis. Free T can fall even when total T looks “okay,” because SHBG rises with weight loss—as seen in deployment studies of conventional infantry as well as SOF.

Frueh has said, in interviews and clinical writing, that hormone panels in this group often look like those of men decades older, and that mental-health clinics almost never order them. That is a legitimate care-gap argument for this population. It is not the same as saying every 30-year-old in the Total Force has Operator Syndrome. Frueh has also noted that SOF sit at the extreme end of the exposure spectrum.

A practical nuance from recent SOF research: some groups have used a higher “grey zone” T threshold (e.g., <400 ng/dL) because operators may start from a higher baseline. That is a hypothesis about this cohort, not an Endocrine Society standard.

How it differs from PTSD

Frueh’s sharpest policy claim is that DoD and VA leaned on the “PTSD easy button.” Many operators do not have classic fear-based PTSD. They have a mix of brain injury, sleep-disordered breathing, hormonal insufficiency, chronic pain, and a nervous system that never downshifts. Labeling that cluster as a primary anxiety disorder and treating only with trauma-focused therapy or SSRIs leaves the physiology untouched. PTSD can still be present; it is just incomplete as the master diagnosis.

Nursing literature has proposed an “SSSS” triage for this group: suicide, sleep, substances, sex hormones—stabilize those before expecting talk therapy to land.

Assessment that actually fits the construct

A useful workup, if someone has years in SOF (or analogous high-blast, high-tempo tactical work) plus several of the domains above:

Full history of blast, jump, dive, and impact exposure—not just “concussions diagnosed”
Overnight sleep study (do not assume a lean athlete cannot have OSA)
Morning fasting total and free T, plus a broader endocrine look (LH/FSH, SHBG, sometimes thyroid, cortisol rhythm)
Cognitive / vestibular / visual screening when headaches, imbalance, or memory complaints are present
Pain, substance use, suicide risk, and relationship function as part of the same visit, not a separate silo
Emerging self-report tools (Operator Syndrome Symptom Scale / OSSS-SR) are being validated; they are adjuncts, not stand-alone tests

Frueh’s own first-pass advice to operators and first responders is blunt: start with a sleep study and a hormone panel. Those two tests often change the formulation.

Treatment logic

There is no single Operator Syndrome protocol. The published and clinical literature describes a stacked approach:

Fix sleep (CPAP when OSA is present; sleep opportunity and circadian hygiene)
Treat confirmed endocrine deficiency, including TRT when criteria are met
Address TBI sequelae (vestibular/vision therapy; some programs use HBOT, TMS—evidence quality varies widely)
Pain and musculoskeletal rehabilitation
Targeted mental-health care (not only trauma protocols): anger, rumination, substance use, suicide
Adjuncts discussed in the SOF community include stellate ganglion block, ketamine, and investigational psychedelic-assisted therapy—promising for some autonomic and mood symptoms, not first-line for everyone
Family and transition support; identity work after leaving the unit

TRT is one tool among many. It is not the syndrome and it is not a readiness shortcut.

Evidence limits (important)

The founding paper is observational pattern recognition, not a prospective epidemiologic study with civilian or conventional-force controls.
Prevalence of the full cluster in the Total Force is unknown. Diagnosed hypogonadism across all active-duty men is low (~0.4% coded); SOF and EOD rates are higher.
Many proposed treatments (HBOT, peptides, some neuromodulation) outrun high-quality trial data.
Generalizing from SEALs and Green Berets with 10–15 years of blast exposure to every service member over 30 is the weakest step in the current Pentagon framing.

Take-home

Operator Syndrome is a useful name for a real, multi-system wear pattern in people who have lived at the far edge of physical and blast exposure for years. Low testosterone is a frequent component, mediated by TBI, sleep loss, and energy deficit—not the whole illness and not a license to screen the entire force at age 30.

Clinically, the construct argues for looking past the PTSD label, checking sleep and hormones early, and treating the cluster rather than the loudest symptom. Policy-wise, it supports intensive, multidisciplinary care for SOF and similarly exposed operators. It does not, by itself, establish that mandatory annual T testing of all men over 30 will improve combat readiness.